Dr. Stanley Deems Braverman, FACS, MD

Dr. Braverman practices at Braverman Eye Center in Hollywood, Florida.

Dr. Braverman's NPI, 1700896701, was assigned on August 9, 2006. Dr. Braverman graduated from University of Miami, Miller School of Medicine in 1976. Dr. Braverman holds Florida license ME36565.

Dr. Braverman's primary practice is Braverman Eye Center, at 1050 N Federal Hwy, Hollywood, FL 33020 in Broward County. The practice phone is (954) 458-2112.

Dr. Braverman's primary practice is Braverman Eye Center in Hollywood, Florida. Dmand AI also links Dr. Braverman to 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Braverman practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Braverman's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Braverman is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Braverman's licenses on file in 4 states: Florida, Georgia, North Carolina and Louisiana.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Braverman treats.

CMS data shows 481 Medicare services from Dr. Braverman across 6 procedure codes in 2024, for 248 Medicare patients. Medicare paid $29,685 for them. Every service was in an office.

CMS counts 248 Medicare patients who saw Dr. Braverman in 2024. The largest group is 75 to 84, with 111 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Braverman's median patient age at 74, with 58% women.

In 2024, Dr. Braverman wrote 5,273 Medicare Part D claims for 1,160 patients. 55% of them were for generic drugs. CMS names the drug for 5,171 of them, across 26 drugs with 11 or more claims each, at $557,433 in total drug cost. In 2023, CMS named 4,987 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Braverman for performance year 2024, reported as part of a group. Dr. Braverman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Braverman.

Dmand AI links Dr. Braverman to 1 clinical trial. Conditions studied include Keratoconus and Corneal Diseases.

CMS Open Payments shows 158 general payments to Dr. Braverman from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 63% of the total. Valeant Pharmaceuticals International paid the most, $2,570.

Dmand AI lists 6 awards for Dr. Braverman, most recently Committee Member: School Board/Broward in 1998.

Dr. Braverman graduated from University of Miami, Miller School of Medicine in 1976. Dr. Braverman is a member of AAO and ACS.

Dr. Braverman is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.